Pancreatic
Research into early diagnostic biomarkers and novel drug combinations is helping tackle one of the deadliest cancer types. Advances in immunotherapy offer new hope.
Nanoparticle immune therapy shows potential to halt pancreatic cancer spread
Pancreatic cancer remains one of the most challenging tumors to treat, partly because it is often discovered at advanced stages when the disease has already spread, or metastasized. About half of pancreatic cancer patients experience metastasis to the liver, which worsens the prognosis for an already life-threatening disease.
Remarkable Women: Cancer survivor Lori Bayer becomes a breast cancer advocate, creating a nonprofit to help others
CHARLESTON, S.C. (WCBD) Ð From small-town girl to globetrotter, Lori Bayer says some of the best years of her life were spent on a journey around the world traveling with her husband.
Blockbuster Weight-Loss Drugs & Cancer Risk: Ozempic Can Affect Pancreas Cells, Experts Weigh In On Whether ThatÕs Worrisome
For people taking GLP-1 drugs, such as the mega-popular weight-loss drug Ozempic (semaglutide) Ñ intended for type 2 diabetes patients and people with obesity Ñ there has been some concern about the effects on the pancreas and whether or not there is a potential risk of pancreatic cancer for people using these medications.
Common chemical in everyday products may raise your liver cancer risk
Scientists from the University of Southern California have found that exposure to a widely used synthetic chemical is linked to a higher risk of developing liver cancer. The chemical, called perfluorooctane sulfate (PFOS), belongs to a group of man-made substances known as per- and polyfluoroalkyl substances (PFAS).
Breakthroughs, Personalization, and the Future of Lymphoma Care
Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies are offering hope for more durable remissions and better quality of life.
Game-Changing AI Unveils Stunning Advances in Lung Disease Detection – DSA
The AI model TD-CNNLSTM-LungNet achieves an exceptional accuracy rate of 96.51% in detecting lung diseases. Combines Convolutional Neural Networks (CNN) and Long Short-Term Memory (LSTM) technologies for superior diagnostics. Capable of accurately differentiating between conditions like pneumonia and COVID-19 using ultrasound images. Enhances radiologists’ decision-making with heat maps and detailed explanations, ensuring transparency. Future plans […]
Pushing the boundaries of radiation treatment: Breakthrough in pancreatic cancer therapy advances to clinical trials
A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for pancreatic cancer, one of the deadliest cancers with limited therapeutic options.
Strutting Into Year 11 With Metastatic Breast Cancer
After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with confidence and self-advocacy.
MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine
“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.
CD5 CAR-T Cell Therapy Receives FDA Orphan Drug Designation for T-Cell Lymphoma
MB-105 is a first-in-class CD5-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory CD5-positive T-cell lymphoma.
Pushing the boundaries of radiation treatment’: Breakthrough in pancreatic cancer therapy advances to clinical trials
A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for pancreatic cancer, one of the deadliest cancers with limited therapeutic options. Researchers have introduced a targeted nasal delivery method that repurposes WR-2721, generically known as amifostine — a radioprotective prodrug historically administered intravenously.
FDA Expands Enhertu Approval to HER2-Ultralow Breast Cancer
T-DXd approved in metastatic HR-positive, HER2-low/ultralow disease following endocrine therapy
